Novavax Stock News

NEW YORK, Jan. 10, 2022 /PRNewswire/ --

Novavax has filed for an EUA to distribute Covavax in South Africa. Here''s why NVAX stock is rising and could shoot up even higher.

Novavax (NVAX) and Serum Institute of India Pvt. Ltd

InvestorPlace - Stock Market News, Stock Advice & Trading Tips With its vaccine candidate still in the running, if you can handle its high volatility, you may want to buy NVAX stock after its latest slide. The post Novavax Remains a Worthwhile Vaccine Play appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. #1 EV Stock Still Flying Under the Radar Interested in Crypto? Read This First

Investors are less enthusiastic about the company''s prospects for its COVID-19 vaccine.

Novavax (NVAX) shares have been volatile recently. News the EUA filing with the FDA for its Covid-19 vaccine NVX-CoV2373 has been further delayed the company only

NEW YORK, Jan. 5, 2022 /PRNewswire/ --

Shares of Novavax, Inc. (NASDAQ:NVAX) have received an average recommendation of Buy from the seven analysts that are presently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokers that have issued []

NEW YORK, Dec. 24, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the Class Period), of the important January 11, 2022 lead plaintiff deadline .

Here are the cases for and against the vaccine maker''s stock.

(RTTNews) - European stocks were flat to slightly higher in thin holiday trade on Friday, with markets in several countries including Germany, Italy, Spain and Switzerland closed for Christmas. London and Paris are open for half-day sessions. Underlying sentiment remained supported after vaccine makers AstraZeneca and Novavax Inc said their

The Indonesian rupiah hit its highest in nearly two months on Friday and was eyeing its best weekly gain since early May, boosted by improving market sentiment on hopes the Omicron coronavirus variant won''t damage the economy too much. Most other Asian emerging currencies clung to narrow ranges against the dollar, while equities were largely mixed in thin trading on Christmas Eve. Global markets, including major indexes on Wall Street, notched modest gains, with the S&P 500 closing at a record high overnight on signs that Omicron is less likely to lead to hospitalization. Vaccine makers AstraZeneca Plc and Novavax Inc said their shots protected against Omicron, and data indicated both Merck''s and Pfizer''s COVID-19 anti-viral pills are effective against the variant, providing another glimmer of hope to the markets. That put pressure on the dollar, which slipped marginally against a basket of currencies. The US dollar index was flat at 96.062, lingering near its one-week low. Analysts at Mizuho Bank termed it as a "Santa pause" which seemed to be more a consequence of heightened uncertainty amid conflicting economic risks and policy signals, than a "risk-on" holiday-cheer rally as more clarity is needed on the Omicron variant.

SK Bioscience Co., a vaccine unit of South Korea''s SK Group, said Friday it has extended an agreement to manufacture a c

GAITHERSBURG, Md., Dec. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and SK bioscience, Co. Limited, a vaccine business subsidiary of Korea-based SK